Coronavirus - we're here to help
From how to access your account online, scam awareness, your wellbeing and our community we're here to help.

Skip to main content
  • Register
  • Help
  • Contact us
  • Log in to HL Account

Intercept Pharmaceuticals Inc (ICPT) USD0.001

Sell:$35.69 Buy:$35.78 Change: $0.18 (0.51%)
NASDAQ:1.28%
Market closed |  Prices as at close on 1 December 2020 | Switch to live prices |
Sell:$35.69
Buy:$35.78
Change: $0.18 (0.51%)
Market closed |  Prices as at close on 1 December 2020 | Switch to live prices |
Sell:$35.69
Buy:$35.78
Change: $0.18 (0.51%)
Market closed |  Prices as at close on 1 December 2020 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Intercept Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics to treat non-viral, progressive liver diseases. The Company's product candidates have the potential to treat orphan and more prevalent diseases for which there are limited therapeutic solutions. The Company's product candidate, obeticholic acid (OCA), is a bile acid analog, a chemical substance that has a structure based on a naturally occurring human bile acid that selectively binds to and activates the farnesoid X receptor (FXR). In addition to OCA, it is developing other bile acid analog compounds targeting FXR and a second dedicated bile acid receptor called TGR5, which is a target of interest for the treatment of type 2 diabetes and other gastrointestinal indications. The Company is also developing other products INT-767 for the treatment of fibrosis and INT-777 for the treatment of type 2 diabetes.

Contact details

Address:
10 Hudson Yards Fl 37
NEW YORK
10001-2160
United States
Telephone:
+1 (646) 7471000
Website:
www.interceptpharma.com

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
ICPT
ISIN:
US45845P1084
Market cap:
$1.23 billion
Shares in issue:
32.99 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Paolo Fundaro
    Independent Chairman of the Board
  • Mark Pruzanski
    President, Chief Executive Officer, Director
  • Sandip Kapadia
    Chief Financial Officer, Treasurer
  • Lisa Bright
    President, International
  • Richard Kim
    President, U.S. Commercial & Strategic Marketing
  • Jerome Durso
    Chief Operating Officer
  • David Ford
    Chief Human Resource Officer
  • Christian Weyer
    Executive Vice President - Research & Development
  • Gail Cawkwell
    Senior Vice President - Medical Affairs, Safety & Pharmacovigilance
  • Ryan Sullivan
    General Counsel, Secretary

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.